Advertisement

Topics

PharmaMar Licenses Fully Synthetic Marine-Derived Payloads To Seattle Genetics

05:43 EST 15 Feb 2018 | Pharmaceutical Processing

PharmaMar will receive an upfront payment of $5 million, followed by development milestones if an antibody-drug conjugate enters clinical development. In addition, PharmaMar is eligible for potential approval and sales milestones as well as royalties.
Contributed Author: 
PhamaMar
Topics: 

Original Article: PharmaMar Licenses Fully Synthetic Marine-Derived Payloads To Seattle Genetics

NEXT ARTICLE

More From BioPortfolio on "PharmaMar Licenses Fully Synthetic Marine-Derived Payloads To Seattle Genetics"

Advertisement
Quick Search
Advertisement
Advertisement